Connor, Clark & Lunn Investment Management (CC&L)
IMDX

Connor, Clark & Lunn Investment Management (CC&L)’s Insight Molecular Diagnostics IMDX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-556
Closed -$40K – 1166
2021
Q3 		$40K Sell
556
-105
-16% -$9.65K ﹤0.01% 1011
2021
Q2 		$76K Buy
+661
New +$64.5K ﹤0.01% 949

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s IMDX Position: Q4 2021 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Insight Molecular Diagnostics (IMDX) in Q4 2021, closing a stake of 556 shares — an estimated $40K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in IMDX in Q2 2021 and held it in 2 quarters. The position peaked at $76K in Q2 2021. 88 funds tracked by Wall St. Rank hold IMDX as of Q4 2021.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Insight Molecular Diagnostics position as of Q4 2021 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 556 Insight Molecular Diagnostics shares in Q4 2021, an estimated $40K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Insight Molecular Diagnostics in Q2 2021 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Insight Molecular Diagnostics position peaked at $76K in Q2 2021.
  • 88 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2021.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2021, filed 10 Feb 2022.